SCHEMBL4290948

SCHEMBL4290948

O=C1COc2ccc(C3=NN(Cc4ccccc4)CC3c3ccccc3)cc2N1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 12/20 0.54
AR P10275 6/20 0.54
NR3C1 P04150 4/20 0.54
PGR P06401 3/20 0.54
PARP1 P09874 3/20 0.50
PDE3B Q13370 1/20 0.46
PDE3A Q14432 1/20 0.46
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
MAPK1 P28482 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
DRD2 P14416 1/20 0.45
DRD4 P21917 1/20 0.45
DRD3 P35462 1/20 0.45
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4297385 0.87 NR3C2 (0.55) NR3C2ARNR3C1PGRPARP1
SCHEMBL4297404 0.87 NR3C2 (0.52) NR3C2ARNR3C1PGRPARP1
SCHEMBL4302037 0.86 NR3C2 (0.54) NR3C2ARNR3C1PGRPARP1
SCHEMBL4288429 0.84 NR3C2 (0.57) NR3C2ARNR3C1PGRPARP1
SCHEMBL4290825 0.83 NR3C2 (0.56) NR3C2ARNR3C1PGRPARP1
SCHEMBL4302071 0.81 NR3C2 (0.51) NR3C2ARNR3C1PGRPARP1
SCHEMBL4297408 0.81 NR3C2 (0.52) NR3C2ARNR3C1PGRPDE3B
SCHEMBL4295836 0.80 NR3C2 (0.54) NR3C2ARNR3C1PGRPARP1
SCHEMBL4290883 0.80 KDM4E (0.56) NR3C2ARNR3C1PGRPARP1
SCHEMBL4295501 0.80 NR3C2 (0.53) NR3C2ARNR3C1PGRPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-08 US disclosed
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-08 US disclosed
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-08 US disclosed
WO-2007077961-A2 FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253687-A1 Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands NR3C2, NR3C1, MC2R NR3C2 1/4885AR 60/4885NR3C1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.